Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.64 |
| ▸ | KDR | P35968 | 8/20 | 0.64 |
| ▸ | FLT1 | P17948 | 5/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.64 |
| ▸ | FLT4 | P35916 | 4/20 | 0.64 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.61 |
| ▸ | SRC | P12931 | 3/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | ABL2 | P42684 | 2/20 | 0.55 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613217 | 0.89 | EGFR (0.66) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL30017110 | 0.89 | EGFR (0.66) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL5437112 | 0.86 | ENPP1 (0.56) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL5214519 | 0.83 | ENPP1 (0.52) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL3949228 | 0.83 | ENPP1 (0.65) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL3954618 | 0.83 | ENPP1 (0.65) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL2190137 | 0.82 | ENPP1 (0.64) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL2188204 | 0.82 | ENPP1 (0.64) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL3204349 | 0.82 | EGFR (0.73) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL4375009 | 0.81 | EGFR (0.63) | EGFRKDRFLT1FGFR1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| EP-1381599-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | EP | disclosed |
| US-7223756-B2 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | disclosed |
| US-20050009850-A1 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| US-20040138240-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| EP-1381599-A1 | QUINAZOLINE DERIVATIVES | Astrazeneca AB (SE) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138240-A1 | Quinazoline derivatives | NQO2, WEE1, CMA1 | EGFR 2914/4885KDR 3721/4885FLT1 2154/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | EGFR 500/4885KDR 3/4885FLT1 2/4885 |
| US-20050009850-A1 | Quinazoline compounds with therapeutic use | CD4, HLA-DRB1, IL5 | EGFR 4564/4885KDR 3728/4885FLT1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.